MAPT and dementia: All the AD patients fulfilled the NIAA-AA criteria for dementia [35] and were designated as AD according to CSF biomarker levels using cut-offs that were >90% specific for AD: Aβ42 < 550ng/L and total tau (T-tau) > 400ng/L [36] (see Table 1).